Toggle Main Menu Toggle Search

Open Access padlockePrints

Randomised control trial of oxygen assist module in preterm infants on high-flow nasal cannula support

Lookup NU author(s): Dr Vrinda Nair, Dr Prakash Kannan Loganathan, Dr Mithilesh Lal

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. Objective: To evaluate the efficacy of automatic oxygen control (A-FiO2) in reducing the extremes of oxygen saturations (SpO2<80% and SpO2>98%) in preterm infants on high-flow nasal cannula (HFNC) respiratory support using Vapotherm Precision Flow. Design: A parallel-arm randomised controlled trial. Setting: A level-III neonatal intensive care unit. Patients: Preterm infants born <33 (23+0 to 32+6) weeks receiving HFNC as respiratory support. Interventions: A-FiO2 versus manual (M-FiO2) oxygen control during the full course of HFNC support. Outcomes: The primary outcome of this study is percentage of time spent in extreme oxygen saturations (<80% and >98%) in preterm infants when receiving HFNC as respiratory support. Secondary outcomes were time with SpO2 between 90% and 95% plus time >95% without supplemental oxygen. Results: 60 infants were randomised equally to either A-FiO2 or M-FiO2 arm. Their baseline characteristics were comparable. They spent a median of 5.3 (IQR: 2.0-8.4) and 6.5 (IQR: 2.9-13.7) days in the study, A-FiO2 and M-FiO2, respectively. The percentage of time spent in SpO2<80% (median of 0.4% (0.1%-0.8%) vs 1.6% (0.6%-2.6%), p=0.002) and >98% (median 0.2% (0.1%-0.9%) vs 1.9% (0.7%-4%), p<0.001) were significantly lower in A-FiO2 compared with M-FiO2. The difference in median percentage of time in target range between the two arms was 26% (81% (74%-93%) in A-FiO2 vs 55% (48%-72%) in M-FiO2). Conclusion: A-FiO2 was associated with statistically significant reduction in the percentage of time spent in extremes of saturation when compared with M-FiO2 in preterm infants receiving HFNC. Trial registration number: NCT04687618.


Publication metadata

Author(s): Nair V, Kannan Loganathan P, Lal MK, Bachman TE, Fantl R

Publication type: Article

Publication status: Published

Journal: Archives of Disease in Childhood: Fetal and Neonatal Edition

Year: 2024

Volume: 109

Issue: 1

Pages: 65-69

Print publication date: 01/01/2024

Online publication date: 14/07/2023

Acceptance date: 29/06/2023

ISSN (print): 1359-2998

ISSN (electronic): 1468-2052

Publisher: BMJ Publishing Group

URL: https://doi.org/10.1136/archdischild-2023-325661

DOI: 10.1136/archdischild-2023-325661

PubMed id: 37451840


Altmetrics

Altmetrics provided by Altmetric


Share